UPDATE: Canaccord Genuity Downgrades AngioDynamics (ANGO) to Hold; Waiting For Navilyst Synergies To Kick In

June 25, 2012 7:39 AM EDT
Get Alerts ANGO Hot Sheet
Price: $15.85 +1.21%

Rating Summary:
    8 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - June 25, 2012 8:22 AM EDT)

Canaccord Genuity downgraded AngioDynamics (NASDAQ: ANGO) from Buy to Hold with a price target of $14.40 (from $16.50).

Analyst, Jason R. Mills, said, "We move to the sidelines on ANGO, as we await evidence the company can deliver stated synergies from the Navilyst acquisition (recently closed) – i.e., $360M in F2013E revenue and $60M in 2013E adjusted EBITDA. We note over 60% of Navilyst’s revenue comes from fluid management, which is a new call point for ANGO (interventional cardiologists) and carries lower gross margins (low 40% range), which, coupled with the normal challenges associated with integrating a large acquisition such as this, presents near-term risk to investors as management works to realize sales and cost synergies."

For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.

Shares of AngioDynamics closed at $12.05 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades

Related Entities

Canaccord Genuity